Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Rituximab (Rituxan) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener's), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related disease (commonly called IgG4-RD), according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Research: Low levels of vitamin D appear to increase child's risk of anemia

Low levels of the "sunshine" vitamin D appear to increase a child's risk of anemia, according to new research led by investigators at the Johns Hopkins Children's Center. The study, published online Oct. 10 in the Journal of Pediatrics, is believed to be the first one to extensively explore the link between the two conditions in children.

22 Oct 2013

Researchers discover link between NOX4 enzyme and osteoporosis

Genkyotex, the leading developer of NOX enzyme inhibitors, announced today that a group of collaborators have discovered a link between the enzyme NOX4 and development of osteoporosis.

21 Oct 2013

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced 12-week results from an ongoing Phase 2b study of VX-509, an investigational oral, selective Janus kinase 3 (JAK3) inhibitor, dosed once or twice daily in people with active rheumatoid arthritis (RA) taking methotrexate

19 Oct 2013

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

Medivir AB (OMX:MVIR-B) today announced preliminary data from two phase III studies conducted by Janssen R&D Ireland evaluating simeprevir in genotype 4 chronic hepatitis C in adult patients with compensated liver disease, and in genotype 1 hepatitis C and HIV-1 co-infected adult patients.

19 Oct 2013

Researchers develop new microfluidic device that could speed monitoring of bacterial infections

There are good bacteria and there are bad bacteria -- and sometimes both coexist within the same species. Take, for instance, Pseudomonas aeruginosa, a microbe common in soil and water.

17 Oct 2013

Simple urine test uses nanotechnology to detect dangerous blood clotting

Life-threatening blood clots can form in anyone who sits on a plane for a long time, is confined to bed while recovering from surgery, or takes certain medications.

17 Oct 2013

Seven promising scientists named 2013 NYSCF - Robertson Investigators

The New York Stem Cell Foundation today named seven of the most promising scientists as its 2013 NYSCF - Robertson Investigators.

16 Oct 2013

Researchers discover how Fra-1 protein protects the liver from drug-induced liver damage

Drug abuse and alcohol are some of the most frequent causes of liver damage, particularly in developed countries. Such kind of liver damage can cause irreversible liver failure and even cancer. Researchers from the Spanish National Cancer Research Centre have discovered an important new protective role of the Fra-1 protein, which neutralizes the damage caused by agents, such as the analgesic drug acetaminophen (Paracetamol).

12 Oct 2013

IVF and chromosome testing: an interview with Dr. Santiago Munné

The Society for Assisted Reproductive Technology (SART) releases every year a report on pregnancy rates by maternal age. The last one shows a decline on implantation rates per embryo from 36% in young women, to 27.3% in women 35-37, 17.5% in 38-40, and less than 10% above 40 years of age.

10 Oct 2013

Constellation Pharmaceuticals awarded grant to facilitate study of epigenetic control of inflammation

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company in the field of epigenetics, today announced that it has been awarded a research grant in collaboration with the University of Pittsburgh School of Medicine from the Cystic Fibrosis Foundation to explore the potential use of BET bromodomain inhibitors for the control of inflammation in cystic fibrosis.

10 Oct 2013

Research points to causes, potential treatment approaches for systemic sclerosis

Using mice, lab-grown cells and clues from a related disorder, Johns Hopkins researchers have greatly increased understanding of the causes of systemic sclerosis, showing that a critical culprit is a defect in the way certain cells communicate with their structural scaffolding

10 Oct 2013

Key findings may have broad implications for future scleroderma therapy

The Scleroderma Research Foundation today said that researchers at The Johns Hopkins University working in a novel mouse model of Stiff Skin Syndrome have made key discoveries that may have broad implications for future scleroderma therapy.

10 Oct 2013

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis.

10 Oct 2013

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Janssen Pharmaceuticals, Inc. announced today the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc.

9 Oct 2013

J&J's Janssen Buys Rights To Hepatitis C Compound From GSK

...

8 Oct 2013

Substance abuse treatment before, after liver transplantation has lower alcohol relapse rates

New research reports that liver transplant recipients who receive substance abuse treatment before and after transplantation have much lower alcohol relapse rates than those untreated or only treated prior to transplantation.

4 Oct 2013

Researchers to develop treatments that may aid in optimal recovery of military from combat injuries

Researchers with Jefferson Orthopedics are using their experience and expertise in post-traumatic joint stiffness to develop treatments that could aid in optimal recovery and restoration of joint function for members of the military who sustain traumatic combat or combat-related injuries.

4 Oct 2013

New classification criteria for systemic sclerosis published in ACR journal

New classification criteria for systemic sclerosis have just been published and are more sensitive than the 1980 criteria, enabling earlier identification and treatment of this disabling autoimmune disease.

3 Oct 2013

Queen's research to investigate how superbug affects cystic fibrosis patients

Queen's University Belfast is to lead a £139,000 study into the way cystic fibrosis sufferers are affected by a superbug that destroys lung function.

2 Oct 2013

Fibrosis News and Research

Further Reading

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Research: Low levels of vitamin D appear to increase child's risk of anemia

Researchers discover link between NOX4 enzyme and osteoporosis

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

Researchers develop new microfluidic device that could speed monitoring of bacterial infections

Simple urine test uses nanotechnology to detect dangerous blood clotting

Seven promising scientists named 2013 NYSCF - Robertson Investigators

Researchers discover how Fra-1 protein protects the liver from drug-induced liver damage

IVF and chromosome testing: an interview with Dr. Santiago Munné

Constellation Pharmaceuticals awarded grant to facilitate study of epigenetic control of inflammation

Research points to causes, potential treatment approaches for systemic sclerosis

Key findings may have broad implications for future scleroderma therapy

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

J&J's Janssen Buys Rights To Hepatitis C Compound From GSK

Substance abuse treatment before, after liver transplantation has lower alcohol relapse rates

Researchers to develop treatments that may aid in optimal recovery of military from combat injuries

New classification criteria for systemic sclerosis published in ACR journal

Queen's research to investigate how superbug affects cystic fibrosis patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News